CL2003002043A1 - Compuestos derivados de tetrahidropiridina sustituidos en posicion 3 y 4; composicion farmaceutica, y sus usos en el tratamiento de enfermedades que estan asociadas con el sistema renina-angiotensina (ras), tales como hipertension, insuficiencia card - Google Patents

Compuestos derivados de tetrahidropiridina sustituidos en posicion 3 y 4; composicion farmaceutica, y sus usos en el tratamiento de enfermedades que estan asociadas con el sistema renina-angiotensina (ras), tales como hipertension, insuficiencia card

Info

Publication number
CL2003002043A1
CL2003002043A1 CL200302043A CL2003002043A CL2003002043A1 CL 2003002043 A1 CL2003002043 A1 CL 2003002043A1 CL 200302043 A CL200302043 A CL 200302043A CL 2003002043 A CL2003002043 A CL 2003002043A CL 2003002043 A1 CL2003002043 A1 CL 2003002043A1
Authority
CL
Chile
Prior art keywords
tetrahydropiridine
renine
ras
insufficiency
hypertension
Prior art date
Application number
CL200302043A
Other languages
English (en)
Spanish (es)
Inventor
Olivier Bezencon
Daniel Bur
Walter Fischli
Lubos Remen
Sylvia Richard-Bildstein
Thomas Weller
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CL2003002043A1 publication Critical patent/CL2003002043A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200302043A 2002-06-27 2003-10-10 Compuestos derivados de tetrahidropiridina sustituidos en posicion 3 y 4; composicion farmaceutica, y sus usos en el tratamiento de enfermedades que estan asociadas con el sistema renina-angiotensina (ras), tales como hipertension, insuficiencia card CL2003002043A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0207102 2002-06-27
PCT/EP2003/004445 WO2004002957A1 (en) 2002-06-27 2003-04-29 Novel tetrahydropyridine derivatives as renin inhibitors

Publications (1)

Publication Number Publication Date
CL2003002043A1 true CL2003002043A1 (es) 2005-01-28

Family

ID=29797098

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200302043A CL2003002043A1 (es) 2002-06-27 2003-10-10 Compuestos derivados de tetrahidropiridina sustituidos en posicion 3 y 4; composicion farmaceutica, y sus usos en el tratamiento de enfermedades que estan asociadas con el sistema renina-angiotensina (ras), tales como hipertension, insuficiencia card

Country Status (16)

Country Link
US (1) US20060009497A1 (enExample)
EP (1) EP1519920A1 (enExample)
JP (1) JP2005532371A (enExample)
CN (1) CN1662498A (enExample)
AU (1) AU2003229746A1 (enExample)
BR (1) BR0312000A (enExample)
CA (1) CA2490138A1 (enExample)
CL (1) CL2003002043A1 (enExample)
IL (1) IL165887A0 (enExample)
MX (1) MXPA04012136A (enExample)
NO (1) NO20050290L (enExample)
PL (1) PL375214A1 (enExample)
RU (1) RU2005102002A (enExample)
TW (1) TW200514772A (enExample)
WO (1) WO2004002957A1 (enExample)
ZA (1) ZA200408423B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060217371A1 (en) * 2003-04-28 2006-09-28 Olivier Bezencon Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors
MXPA05011478A (es) * 2003-04-29 2005-12-12 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,6-tetrahidropiridina 3,4-disustituidos novedosos.
CA2521938A1 (en) * 2003-04-30 2004-11-11 Actelion Pharmaceuticals Ltd 9-azabicyclo[3.3.1]non-6-ene derivatives with a heteroatom at the 3-position as renin inhibitors
EP1622564A2 (en) * 2003-05-02 2006-02-08 Actelion Pharmaceuticals Ltd. Diazabicyclononene derivatives
WO2004105738A2 (en) * 2003-05-30 2004-12-09 Actelion Pharmaceuticals Ltd Use of tetrahydropyridine derivatives
CN1863773A (zh) * 2003-10-09 2006-11-15 埃科特莱茵药品有限公司 四氢吡啶衍生物
JP2007508262A (ja) * 2003-10-13 2007-04-05 アクテリオン　ファマシューティカルズ　リミテッド 新規ジアザビシクロノネン誘導体およびその使用
US20070111989A1 (en) * 2003-12-05 2007-05-17 Olivier Bezencon Novel diazabicyclononene derivatives and use
WO2005068427A1 (ja) * 2004-01-14 2005-07-28 Takeda Pharmaceutical Company Limited カルボキサミド誘導体およびその用途
RU2426532C2 (ru) * 2004-03-17 2011-08-20 Новартис Аг Применение органических соединений
CA2577084A1 (en) 2004-08-25 2006-03-02 Olivier Bezencon Bicyclononene derivatives as renin inhibitors
GB0428526D0 (en) * 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0504850D0 (en) * 2005-03-09 2005-04-13 Novartis Ag Organic compounds
GB0510810D0 (en) * 2005-05-26 2005-06-29 Novartis Ag Organic compounds
AU2006253805A1 (en) * 2005-05-27 2006-12-07 Actelion Pharmaceuticals Ltd. Novel piperidine carboxylic acid amide derivatives
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
WO2007049224A1 (en) * 2005-10-25 2007-05-03 Actelion Pharmaceuticals Ltd Novel hexahydro- or octahydro-cyclopenta[c]pyrrole derivatives
RU2425032C2 (ru) 2006-02-02 2011-07-27 Актелион Фармасьютикалз Лтд Вторичные амины в качестве ингибиторов ренина
CA2642424A1 (en) * 2006-03-03 2007-09-07 Actelion Pharmaceuticals Ltd. Primary amines as renin inhibitors
NZ571595A (en) * 2006-03-08 2010-06-25 Actelion Pharmaceuticals Ltd New amines
EP1908471A1 (en) * 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors
AU2008253519A1 (en) 2007-05-24 2008-11-27 Merck Frosst Canada Ltd Novel case of renin inhibitors
EP2190811B1 (en) 2007-08-20 2013-08-07 Merck Canada Inc. Renin inhibitors
US8889714B2 (en) 2008-05-05 2014-11-18 Actelion Pharmaceuticals Ltd. 3,4-substituted piperidine derivatives as renin inhibitors
TWI471289B (zh) 2010-06-11 2015-02-01 Rhodes Technologies 使三級胺進行ｎ－脫烷反應之方法
CA2936749C (en) 2010-06-11 2019-07-09 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
CN117865941B (zh) * 2024-03-13 2024-06-28 上海方予健康医药科技有限公司 取代哌啶化合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376666A (en) * 1992-11-30 1994-12-27 The Du Pont Merck Pharmaceutical Company Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl
PL193686B1 (pl) * 1995-09-07 2007-03-30 Hoffmann La Roche Pochodne piperydyny, środki lecznicze zawierającepochodne piperydyny, sposoby wytwarzania tych pochodnych oraz zastosowanie pochodnych
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors

Also Published As

Publication number Publication date
BR0312000A (pt) 2005-03-22
PL375214A1 (en) 2005-11-28
NO20050290L (no) 2005-01-19
TW200514772A (en) 2005-05-01
ZA200408423B (en) 2005-10-11
US20060009497A1 (en) 2006-01-12
RU2005102002A (ru) 2005-09-20
MXPA04012136A (es) 2005-04-19
EP1519920A1 (en) 2005-04-06
WO2004002957A1 (en) 2004-01-08
AU2003229746A1 (en) 2004-01-19
CN1662498A (zh) 2005-08-31
JP2005532371A (ja) 2005-10-27
CA2490138A1 (en) 2004-01-08
IL165887A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
DK1656372T3 (da) 2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
EP1140840A4 (en) -G (V) -CARBOXYARYL SUBSTITUTED DIPHENYL UREASINE AS RAF KINASE INHIBITORS
CL2008001813A1 (es) Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04).
ATE509634T1 (de) Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
BR0301247B1 (pt) sistema cirérgico de passagem de lÍquido.
DE50306232D1 (de) Ampholytisches copolymer und dessen verwendung
DE602004014283D1 (de) System zur Einführung von mehreren Medizinprodukten
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
DE60333294D1 (de) Kontrollierte verabreichung von arzneien
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
CL2007003352A1 (es) Compuestos derivados de heteromonociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades circulatorias, enfermedades metabolicas y/o enfermedades del sistema nervioso cen
CL2008001721A1 (es) Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
CL2004000930A1 (es) Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos.
BRPI0415709A (pt) esquemas terapêuticos para antagonistas de baff
DE60317887D1 (de) System zur verabreichung therapeutischer substanzen
DK1620113T3 (da) Topisk formulering af ivermectin til behandling af dermatologiske lidelser
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
SV2008002856A (es) 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas
AR057239A1 (es) Inmunoglobulinas
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
PA8577701A1 (es) Polipeptido t20 pegilado
BRPI0620229A8 (pt) formulação
NO20062824L (no) 1,3-Difenylprop-2-en-1-on-avledete forbindelser, fremgangsmater for fremstilling derav, samt anvendelse av samme